Articles: sepsis.
-
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue · Mar 2009
Randomized Controlled Trial[Clinical effects of ulinastatin and thymosin alpha1 on immune-modulation in septic patients].
To analyze clinical effect of immuno-modulatory therapy with ulinastatin and thymosin alpha1 on patients with sepsis. ⋯ The immuno-modulation therapy of ulinastatin and thymosin alpha1 can remarkably improve the duration of MV and the development rate of MODS and mortality rate on 28 days in the patients with sepsis, probably due to its effect in ameliorating the immuno-imbalance state of the patients. However, the duration of infection and length of ICU stay are not effected.
-
Langenbecks Arch Surg · Mar 2009
Randomized Controlled Trial Comparative StudyProcalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study.
Adequate indication and duration of administration are central issues of modern antibiotic treatment in intensive care medicine. The biochemical variable procalcitonin (PCT) is known to indicate systemically relevant bacterial infections with high accuracy. In the present study, we aimed to investigate the clinical usefulness of PCT for guiding antibiotic treatment in surgical intensive care patients with severe sepsis. ⋯ Monitoring of PCT is a helpful tool for guiding antibiotic treatment in surgical intensive care patients with severe sepsis. This may contribute to an optimized antibiotic regimen with beneficial effects on microbial resistances and costs in intensive care medicine.
-
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue · Mar 2009
Randomized Controlled Trial[Effect of continuous blood purification and thymosin alpha1 on the cellular immunity in patients with severe sepsis: a prospective, randomized, controlled clinical trial].
To discuss the effect of continuous blood purification (CBP), thymosin alpha1 and combined therapy on cellular immunity in patients with severe sepsis. ⋯ CBP and thymosin alpha1 could increase cellular immunity in patients with severe sepsis, promote recovery of organ function and improve prognosis. The effect of CBP appears earlier and more pronounced. Combined treatment can be more effective.
-
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue · Mar 2009
Randomized Controlled Trial[A clinical study of the serum vascular endothelial growth factor in patients with severe sepsis].
To examine the dynamic changes in serum vascular endothelial growth factor (VEGF) levels in patients with severe sepsis, and to investigate its relationship with acute physiology and chronic health evaluation II (APACHE II) score and some clinical parameters of patients. ⋯ The VEGF levels are elevated at onset in severe sepsis patients. The VEGF levels lowered along with the course of the disease in survival group, but it lowers inconspicuously in death group. VEGF levels can reflect the severity of sepsis in certain degree.
-
Critical care medicine · Feb 2009
Randomized Controlled Trial Multicenter StudyAlkaline phosphatase treatment improves renal function in severe sepsis or septic shock patients.
Alkaline phosphatase (AP) attenuates inflammatory responses by lipopolysaccharide detoxification and may prevent organ damage during sepsis. To investigate the effect of AP in patients with severe sepsis or septic shock on acute kidney injury. ⋯ In severe sepsis and septic shock, infusion of AP inhibits the upregulation of renal inducible NO synthase, leading to subsequent reduced NO metabolite production, and attenuated tubular enzymuria. This mechanism may account for the observed improvement in renal function.